Latest from Bell Potter.....
Bell Potter thinks that this biopharmaceutical company is an ASX share to buy right now.Last week, the broker retained its buy rating with a new price target of $22.25.
This implies potential upside of 55% for investors from current levels. It said:Clinuvel maintains a lean, vertically integrated business model that we expect to generate EBIT margins of ~50% in FY24 and FY25.
Scenesse remains the only approved drug for EPP patients globally, with the most advanced competitors still ~3-4 years away, if successful.
Latest from Bell Potter.....Bell Potter thinks that this...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.72 |
Change
-0.100(0.67%) |
Mkt cap ! $737.1M | |||
| Open | High | Low | Value | Volume |
| $14.80 | $14.97 | $14.60 | $600.3K | 40.64K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 324 | $14.69 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.75 | 100 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| CUV (ASX) Chart |